Cell Source, Inc. announced that it is planning to commence a Phase I/II clinical trial with a cell therapy treatment that aspires to significantly reduce the need for immune suppression treatment for both donor-matched and "mismatched" bone marrow transplant patients. This treatment could potentially lead to a substantial increase in patient survival rates.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +300.00% | -.--% | -99.83% |
03-22 | Cell Source, Inc. announced that it has received $4.76017 million in funding | CI |
2023 | Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-99.83% | 32.82K | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- CLCS Stock
- News Cell Source, Inc.
- Cell Source, Inc. to Commence a Phase I/II Clinical Trial with a Cell Therapy Treatment